BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed RNAC catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:7d6b065757fadb90925d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:RNAC P2 readout (est.): SLE-001
DESCRIPTION:Descartes-08 for Patients With Systemic Lupus Erythematosus\nNC
 T06038474 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Cartesian Therapeuti
 cs\nPrimary completion date (ESTIMATED)\; top-line results usually follow 
 later.\nTicker RNAC (confidence 0.9)\nSource: https://clinicaltrials.gov/s
 tudy/NCT06038474\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06038474
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7d43f95d77d293a7b4b8@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:RNAC P3 readout (est.): Investigating an mRNA CAR T-cell Therapy\, 
 Known as Descartes-08\, as a Potential Approach to Treat Myasthenia Gravis
DESCRIPTION:Investigating an mRNA CAR T-cell Therapy\, Known as Descartes-0
 8\, as a Potential Approach to Treat Myasthenia Gravis\nNCT06799247 | PHAS
 E3 | ACTIVE_NOT_RECRUITING | sponsor: Cartesian Therapeutics\nPrimary comp
 letion date (ESTIMATED)\; top-line results usually follow later.\nTicker R
 NAC (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06799247
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06799247
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
